2006
DOI: 10.1016/j.jaci.2006.01.015
|View full text |Cite
|
Sign up to set email alerts
|

Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
430
0
23

Year Published

2009
2009
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 567 publications
(462 citation statements)
references
References 328 publications
9
430
0
23
Order By: Relevance
“…Medical conditions for which Ig is considered an alternative or second-line treatment option, or not described uniformly among the cited guidelines and consensus papers, were designated "conditional," as were diagnoses for which there was insufficient evidence to support Ig over other interventions. For example, conditions in the study by Orange et al (2006), which used descriptive evidence categories, including "probably beneficial" and "might provide benefit," were categorized as "conditional" in this analysis.…”
Section: What Is Already Known About This Subjectmentioning
confidence: 99%
“…Medical conditions for which Ig is considered an alternative or second-line treatment option, or not described uniformly among the cited guidelines and consensus papers, were designated "conditional," as were diagnoses for which there was insufficient evidence to support Ig over other interventions. For example, conditions in the study by Orange et al (2006), which used descriptive evidence categories, including "probably beneficial" and "might provide benefit," were categorized as "conditional" in this analysis.…”
Section: What Is Already Known About This Subjectmentioning
confidence: 99%
“…Immunotherapy on the basis of the passive administration of human plasma-derived IgG has been used for three decades in clinical applications, with improvement of a large panel of disease conditions like immunodeficiencies, infections, or autoimmune diseases (20,21). Preclinical and clinical studies have underscored the efficacy against various infectious agents of polyclonal IgM-enriched preparations administered by the systemic route (22)(23)(24)(25)(26).…”
mentioning
confidence: 99%
“…5 El tratamiento de estas enfermedades consiste en la administración periódica (de por vida) de inmunoglobulina G humana (IgG) con el objeto de mantener niveles séricos de IgG similares a los de una persona sana. [7][8][9][10][11] El hecho de que los pacientes con defectos en la producción de anticuerpos requieran recibir IgG cada tres o cuatro semanas obliga al paciente y sus familiares a desplazarse a un centro de atención médica donde pueda aplicarse el medicamento, con la consiguiente pérdida de días de escuela para los pacientes y de trabajo para los padres. Además, el retraso diagnóstico puede ocasionar daño irreversible en los órganos afectados por infecciones recurrentes.…”
Section: Discussionunclassified